The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...

Resolving the mechanism of RXR ligand-dependent NR4A-RXR nuclear receptor heterodimer activation requires a diverse ligand set that includes heterodimer-selective agonists.

GPCRs (G-protein-coupled receptors) represent the largest family of membrane receptors currently targeted by approved drugs. It is estimated that approximately 700 approved drugs target GPCRs ...

Various approaches to such protein redesign have drawbacks. Traditional methods include time-consuming trial and error efforts, and many models in the emerging field ...